viewgenedrive PLC

Epistem signs drug discovery collaboration with Novartis


Shares in biotechnology and research services company, Epistem (AIM: EHP) jumped 16% after the company announced that it had entered into a research and development collaboration with Novartis (VTX:NOVN).

The deal will see Novartis pay Epistem US$4 million in an upfront payment and provide research funding for 2 years to identify new drug targets and therapeutics across a wide range of disease areas.  Epistem will provide its stem cell expertise and drug discovery experience with Novartis’s knowledge of disease pathways and bioinformatics. Novartis will have an option to licence any drug targets in exchange for license fees, milestone payments and royalties.

Matthew Walls, Epistem CEO, commented:

"The collaboration will enable us to accelerate the development of our existing targets with a world class pharmaceutical collaborator and to jointly explore disease opportunities in regenerative medicine".

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Nexus Minerals yields up to 5 metres at 17.91 g/t gold at Wallbrook prospects

Nexus Minerals Ltd (ASX:NXM)’s Andy Tudor speaks with Proactive about its ambitious drill campaign at the Branches and Solomon prospects, part its Wallbrook Gold Project in WA. The MD noted that while this was an early-stage project “the scale of metal endowment of this large mineralised system...

15 hours, 33 minutes ago

2 min read